Dorchester Wealth Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $1.31M | Sell |
14,158
-200
| -1% | -$18K | 0.26% | 62 |
|
|
2024
Q3 | $1.2M | Sell |
14,358
-200
| -1% | -$15.3K | 0.22% | 68 |
|
|
2024
Q2 | $999K | Sell |
14,558
-1,240
| -8% | -$82.8K | 0.19% | 73 |
|
|
2024
Q1 | $1.16M | Sell |
15,798
-170
| -1% | -$13.1K | 0.21% | 76 |
|
|
2023
Q4 | $1.29M | Sell |
15,968
-378
| -2% | -$29.4K | 0.24% | 64 |
|
|
2023
Q3 | $1.22M | Buy |
16,346
+13,406
| +456% | +$1.03M | 0.25% | 64 |
|
|
2023
Q2 | $227K | Sell |
2,940
-30
| -1% | -$2.39K | 0.05% | 134 |
|
|
2023
Q1 | $246K | Sell |
2,970
-990
| -25% | -$82K | 0.05% | 137 |
|
|
2022
Q4 | $340K | Sell |
3,960
-740
| -16% | -$58.6K | 0.08% | 113 |
|
|
2022
Q3 | $290K | Sell |
4,700
-300
| -6% | -$18.9K | 0.06% | 126 |
|
|
2022
Q2 | $309K | Buy |
5,000
+1,710
| +52% | +$106K | 0.06% | 126 |
|
|
2022
Q1 | $244K | Buy |
3,290
+100
| +3% | +$6.39K | 0.04% | 146 |
|
|
2021
Q4 | $232K | Buy |
3,190
+50
| +2% | +$3.44K | 0.05% | 136 |
|
|
2021
Q3 | $219K | Hold |
3,140
| – | – | 0.05% | 137 |
|
|
2021
Q2 | $216K | Buy |
+3,140
| New | +$210K | 0.05% | 145 |
|
|
2020
Q1 | – | Sell |
-81,078
| Closed | -$5.27M | – | 122 |
|
|
2019
Q4 | $5.27M | Buy |
81,078
+610
| +0.8% | +$39.7K | 1.47% | 28 |
|
|
2019
Q3 | $5.1M | Buy |
80,468
+10
| +0% | +$654 | 1.5% | 26 |
|
|
2019
Q2 | $5.44M | Buy |
80,458
+90
| +0.1% | +$5.92K | 1.61% | 24 |
|
|
2019
Q1 | $5.22M | Buy |
80,368
+1,739
| +2% | +$116K | 1.59% | 25 |
|
|
2018
Q4 | $4.92M | Sell |
78,629
-9
| -0% | -$629 | 1.71% | 22 |
|
|
2018
Q3 | $6.07M | Buy |
78,638
+13,835
| +21% | +$1.04M | 1.89% | 19 |
|
|
2018
Q2 | $4.59M | Sell |
64,803
-2,050
| -3% | -$145K | 1.51% | 25 |
|
|
2018
Q1 | $5.04M | Sell |
66,853
-560
| -0.8% | -$44.5K | 1.7% | 21 |
|
|
2017
Q4 | $4.83M | Sell |
67,413
-2,245
| -3% | -$170K | 1.53% | 23 |
|
|
2017
Q3 | $5.64M | Buy |
69,658
+1,048
| +2% | +$80.1K | 1.81% | 17 |
|
|
2017
Q2 | $4.86M | Buy |
68,610
+196
| +0.3% | +$13K | 1.67% | 21 |
|
|
2017
Q1 | $4.65M | Buy |
68,414
+5,065
| +8% | +$356K | 1.62% | 24 |
|
|
2016
Q4 | $4.54M | Buy |
63,349
+1,904
| +3% | +$142K | 1.65% | 22 |
|
|
2016
Q3 | $4.86M | Buy |
61,445
+2,630
| +4% | +$214K | 1.81% | 20 |
|
|
2016
Q2 | $4.91M | Buy |
58,815
+24,280
| +70% | +$2.15M | 1.82% | 18 |
|
|
2016
Q1 | $3.17M | Buy |
34,535
+22,460
| +186% | +$2.03M | 1.2% | 30 |
|
|
2015
Q4 | $1.22M | Buy |
12,075
+4,625
| +62% | +$481K | 0.51% | 48 |
|
|
2015
Q3 | $974K | Buy |
7,450
+2,400
| +48% | +$267K | 0.36% | 50 |
|
|
2015
Q2 | $738K | Buy |
+5,050
| New | +$552K | 0.24% | 63 |
|
Other funds holding GILD
Dorchester Wealth Management's GILD Position: Q4 2024 in Review
Dorchester Wealth Management reduced its Gilead Sciences (GILD) stake by 1.4% in Q4 2024, selling an estimated $18K and leaving 14,158 shares worth $1.31M. The position accounts for 0.26% of the portfolio, ranked #62.
Dorchester Wealth Management first reported a position in GILD in Q2 2015 and has held it in 34 quarters since. The position peaked at $6.07M in Q3 2018. 1,887 funds tracked by Wall St. Rank hold GILD as of Q4 2024.
- Dorchester Wealth Management held 14,158 shares of Gilead Sciences worth $1.31M as of Q4 2024.
- Dorchester Wealth Management sold 200 Gilead Sciences shares in Q4 2024, an estimated $18K.
- Gilead Sciences made up 0.26% of Dorchester Wealth Management's portfolio in Q4 2024, its #62 holding.
- Dorchester Wealth Management first reported a position in Gilead Sciences in Q2 2015 and has held it in 34 quarters since.
- Dorchester Wealth Management's Gilead Sciences position peaked at $6.07M in Q3 2018.
- 1,887 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.
Based on Dorchester Wealth Management's 13F filing for Q4 2024, filed 4 Feb 2025.